Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: A preliminary study

International Journal of Impotence Research

Volumn 22, Issue 2, 2010, Pages 115-119

  Verit, A ^a   Savas, M ^a   Ciftci, H ^a   Aksoy, N ^a   Taskin, A ^a   Topal, U ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HYDROGEN PEROXIDE; TADALAFIL;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERECTILE DYSFUNCTION; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOLINES; CARDIOVASCULAR SYSTEM; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS;

EID: 77949656033     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2009.58     Document Type: Article

References (32)

1. Frajese GV, Pozzi F. New achievement and novel therapeutic applications of PDE5 inhibitors in older males. J Endocrinol Invest 2005; 28: 45-50.
2. Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 2005; 68: 2131-2142.
3. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003; 92: 26-36.
4. Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. Eur J Pharmacol 2008; 589: 180-187.
5. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008; 26: 501-507.
6. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardio-vascular vessels. Curr Top Med Chem 2007; 7: 437-454.
7. Habek M, Petraviæ D. Stroke-an adverse reaction to sildenafil. Clin Neuropharmacol 2006; 29: 165-167.
8. Lue TF, Broderick GA. Evaluation of nonsurgical management of erectile dysfunction and premature ejaculation. In: Wein AJ, Kavoussi LR, Novick AJ, Partin AW, Peters CA (eds). Campbell-Walsh Urology, 9th edn. Saunders: Philadelphia, 2007, vol 1, pp 750-787.
9. Eleuteri E, Magno F, Gnemmi I, Carbone M, Colombo M, La Rocca G et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009; 14: 2230-2237.
10. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4: 89-102.
11. Perk H, Armagan A, Naziroǧlu M, Soyupek S, Hoscan MB, SütcüR et al. Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men. J Clin Pharm Ther 2008; 33: 635-640.
12. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S et al. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 2009; 181: 899-906.
13. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-17535.
14. Mackness B, Durrington P,McElduff P, Yarnell J, Azam N,WattM et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
15. Verit FF, Celik H, Yazgan P, Erel O, Geyikli I. Paraoxonase-1 activity as a marker of atherosclerosis is not associated with low bone mineral density in healthy postmenopausal women. Arch Gynecol Obstet 2007; 275: 353-359.
16. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1103-1108.
17. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335.
18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.
19. Verit FF, Erel O, Celik N. Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease. Hum Reprod 2008; 23: 100-104.
20. Foresta C, De Toni L, Di Mambro A, Garolla A, Ferlin A, Zuccarello D. The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J Sex Med 2009; 6: 369-372.
21. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol 2007; 51: 1411-1417.
22. Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology 2006; 68: 47-60.
23. Kontaras K, Varnavas V, Kyriakides ZS. Does sildenafil cause myocardial infarction or sudden cardiac death? Am J Cardiovasc Drugs 2008; 8: 1-7.
24. Görge G, Flüchter S, Kirstein M, Kunz T. Sex, erectile dysfunction, and the heart: a growing problem. Herz 2003; 28: 284-290.
25. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009; 181: 245-251.
26. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 2006; 13: 129-142.
27. De Young L, Yu D, Bateman RM, Brock GB. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004; 25: 830-836.
28. Speranza L, Franceschelli S, Pesce M, Vinciguerra I, De Lutiis MA, Grilli A et al. Phosphodiesterase type-5 inhibitor and oxidative stress. Int J Immunopathol Pharmacol 2008; 21: 879-889.
29. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004; 4: 211-217.
30. Yildiz A, Gur M, Demirbag R, Yilmaz R, Akyol S, Aslan M et al. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin Biochem 2008; 41: 779-784.
31. Ozkök E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008; 14: CR536-CR542.
32. Ciftci H, Yeni E, Savas M, Verit A, Celik H. Paraoxonase activity in patients with erectile dysfunction. Int J Impot Res 2007; 19: 517-520.